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Abstract
Background: Tuberculosis (TB) is the most frequent co-infection in HIV-infected individuals still presenting diagnostic
difficulties particularly in developing countries. Recently an assay based on IFN-gamma response to M. tuberculosis RD1
peptides selected by computational analysis was developed whose presence is detected during active TB disease.
Objective of this study was to investigate the response to selected RD1 peptides in HIV-1-infected subjects with or
without active TB in a country endemic for TB and to evaluate the change of this response over time.
Methods: 30 HIV-infected individuals were prospectively enrolled, 20 with active TB and 10 without. Among those with
TB, 12 were followed over time. IFN-gamma response to selected RD1 peptides was evaluated by enzyme-linked
immunospot (ELISPOT) assay. As control, response to RD1 proteins was included. Results were correlated with
immune, microbiological and virological data.
Results: Among patients with active TB, 2/20 were excluded from the analysis, one due to cell artifacts and the other
to unresponsiveness to M. tuberculosis antigens. Among those analyzable, response to selected RD1 peptides evaluated
as spot-forming cells was significantly higher in subjects with active TB compared to those without (p = 0.02). Among
the 12 TB patients studied over time a significant decrease (p =< 0.007) of IFN-gamma response was found at completion
of therapy when all the sputum cultures for M. tuberculosis were negative. A ratio of RD1 peptides ELISPOT counts over
CD4+ T-cell counts greater than 0.21 yielded 100% sensitivity and 80% specificity for active TB. Conversely, response to
RD1 intact proteins was not statistically different between subjects with or without TB at the time of recruitment;
however a ratio of RD1 proteins ELISPOT counts over CD4+ T-cell counts greater than 0.22 yielded 89% sensitivity and
70% specificity for active TB.
Conclusion: In this pilot study the response to selected RD1 peptides is associated with TB disease in HIV-infected
individuals in a high TB endemic country. This response decreases after successful therapy. The potential of the novel
approach of relating ELISPOT spot-forming cell number and CD4+ T-cell count may improve the possibility of diagnosing
active TB and deserves further evaluation.
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Background
The World Health Organization has called for "urgent and
extraordinary actions" to control tuberculosis (TB) in
Africa [1]. Africa contains 9 of the 22 countries with the
highest TB burden and the predominant factor driving the
increased incidence of TB in these areas is the high preva-
lence of Human Immunodeficiency virus (HIV) infection
[2-4].
HIV-1 co-infection significantly affects the progression of
M. tuberculosis infection [5,6]. Innovative diagnostic tools
for TB, new and enhanced treatment strategies, plus vali-
dation of markers that indicate efficacy of treatment, are
needed to help combat the epidemic of dual HIV/TB co-
infection. These need to be shown to be useful in TB-
endemic settings.
A recent breakthrough in the diagnosis of M. tuberculosis
infection has been the development of T-cell-based inter-
feron(IFN)-gamma release assays (IGRAs) that use anti-
gens belonging to M. tuberculosis region of difference-1
(RD1), including early secreted antigenic target-6 [ESAT-
6] and culture filtrate protein 10 [CFP-10]). Two commer-
cial IGRAs are now available, and evidence reviewed else-
where [7-10] suggests that they are more specific than
tuberculin skin test (TST), and correlate better with mark-
ers of TB infection in low incidence settings. Importantly,
IGRAs are less affected by bacillus Calmette-Guerin (BCG)
vaccination than the TST.
On the basis of this line of research, we recently reported
an in vitro immune diagnostic enzyme-linked immunos-
pot (ELISPOT) assay for IFN-gamma whose novelty con-
sists in the use of RD1 peptides, which are multiepitopic
and are selected by computational analysis [11-14]. The
response to these peptides can be detected in subjects with
ongoing M. tuberculosis replication, such as during active
TB disease and/or recent infection, and decreases during
TB therapy [15-17]. These studies conducted in Italy, a
country with a low TB incidence (less than 10/100.000
population [18]), suggest that this assay may have a clini-
cal value as a supplemental tool for diagnosis and moni-
toring of active TB. However, it is not known if this assay
may be potentially useful also in a setting with high M.
tuberculosis transmission. Moreover, it has been suggested
that the clinical usefulness of assays measuring in vitro
response to RD1 encoded antigens may be limited in
patients with HIV-induced immunosuppression [19,20]
although in studies in which ELISPOT-based assays were
used, encouraging sensitivity (73–90%) for active HIV-
associated TB was found in both children and adults [21-
23].
Recently Rangaka et al. [24], reported an interesting
approach to better identify patients with active TB among
HIV+ patients. This method directly correlates the ELIS-
POT results of RD1 proteins stimulation with the CD4+ T-
cell count of each single patient.
Thus, objectives of this pilot study in HIV-infected indi-
viduals from a tropical setting were: i) to evaluate whether
this selected RD1 peptide assay may help in providing evi-
dence of diagnosis of active TB in an endemic country; ii)
to evaluate changes in the response to RD1 peptides dur-
ing therapy; iii) to use the approach suggested by Rangaka
et al. [24], as an additional tool for the identification of
active TB; iv) to compare the results obtained with RD1
peptide assay with the response to RD1 intact proteins, an
other in-house RD1 assay largely used in the literature
[23-26].
Methods
Patient population and study design
HIV-1-infected adults with initial episode of sputum
smear-positive pulmonary TB were recruited from the
National Tuberculosis and Leprosy Programme Clinic at
Mulago Hospital in Kampala, Uganda. Diagnosis of pul-
monary TB was based on sputum culture confirmation.
Pregnancy, extrapulmonary TB or chronic debilitating dis-
eases, a Karnofsky performance scale score of ≤ 60 (patient
unable to care for self and requiring the equivalent of hos-
pital or institutional care), or CD4+ T-cell counts of ≤ 100
cells/μl were exclusion criteria. Chest radiographs were
interpreted by a single experienced chest physician, who
was masked to the patients' clinical status and laboratory
studies, using the standard scheme of the U.S. National
Tuberculosis and Respiratory Disease Association and
were classified as normal, minimal, moderately advanced,
or far-advanced disease [27,28]. The study protocol was
approved by the institutional review boards at University
Hospitals of Cleveland Case Western Reserve University
and the Uganda National AIDS Research Subcommittee.
All subjects gave informed consent for study participation.
Patients were treated with standard chemotherapy for pul-
monary TB [27]. From January 2006 to January 2007,
patients meeting the above-mentioned criteria were
recruited.
TST was not performed in this study because of the poor
specificity in areas of high BCG coverage like Uganda and
where there is high prevalence of environmental myco-
bacteria.
No antiretroviral therapy was performed. Heparinized
blood was obtained from subjects at enrolment and, in a
smaller group (n = 12), at 6 months after initiation of
treatment and in 9 of them also after 3 months of therapy.
Complete blood counts and sputum examination were
performed monthly during treatment. Follow-up chest
radiographs were obtained at the end of the specific treat-BMC Infectious Diseases 2008, 8:11 http://www.biomedcentral.com/1471-2334/8/11
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ment. A group of healthy HIV-1-infected subjects without
active TB (chest radiograph and sputum smear negative)
with CD4+ T-cell counts over 100 cells/μl were recruited as
control group.
Plasma HIV-RNA load was detected by PCR by HIV Mon-
itor test (1.5 Test) (Roche, Indianapolis, Indiana). CD4+
T-cell counts were evaluated by immunostaining and flu-
orescence activated cell sorter (FACS) analysis [29].
ELISPOT assays
The experimental procedures were conducted in Uganda
at the Immunology laboratories of TB Reserarch Unit with
fresh blood samples. The ELISPOT plates were shipped
and read in Italy (see below). Briefly the peripheral blood
mononuclear cells (PBMC) were isolated as described
[15,16]. 2.5 × 105 PBMC were seeded (200 μL/well in
duplicate) into microtiter 96 well UNIFILTER®  Micro-
plates (Whatman plc, UK) pre-coated with capture anti-
body (Ab) (IFN-γ coating monoclonal, M-700A, Pierce-
Endogen Inc. Rockford, Illinois). PBMC were then stimu-
lated with ESAT-6 and CFP-10 peptide pools (50 μg/mL
and 6 μg/mL respectively). ESAT-6 and CFP-10 intact pro-
teins (2 μg/mL each) (Lionex, Germany) were used as pos-
itive controls for the specific responses to M. tuberculosis
and were incubated overnight at 37°C, with 5% CO2. On
the next morning, the cells were washed off, and the plates
were incubated with a biotinylated capping antibody
(Pierce-Endogen). On the next day, the plates were
washed extensively and were incubated with streptavidin-
horseradish peroxidase (Dako, Glostrup, Denmark). The
plates then were developed with AEC substrate (Pierce),
after a final washing step. Spots were then counted by an
automated ELISA-Spot assay video analysis system
(AELVIS, Hannover, Germany). Evaluated spots had a size
>15 U (1 U = 50 μm2).
When the average number of spot-forming cells in dupli-
cate wells of stimulated cultures exceeded that in controls
by 10 spot-forming cells and, at the same time was above
34 spot-forming cells/million PBMC the responses were
scored as positive [26]. To obtain the absolute value, the
number of spot-forming cells in the negative controls was
subtracted from the number of spot-forming cells in the
stimulated cultures. Clinicians were blinded to the labora-
tory test results and laboratory personnel were blinded to
the status of the patients.
Statistical analysis
Median and range of values were calculated. The Mann-
Whitney U test was used to compare continuous variables,
and Chi square was used for categorical variables. Corre-
lation between the response to the RD1 assays and CD4+
T-cell counts was calculated by the Person's r coefficient.
Analysis was carried out with SPSS v 14 for Windows
(SPSS Italia srl, Bologna, Italy). Receiver-operator charac-
teristic analysis was performed using Prism 4 software
(GraphPad) [30].
Results
Characteristics of enrolled subjects
We enrolled 20 consecutive HIV-infected individuals with
active pulmonary TB. Ten controls without active TB were
also recruited. The demographic and clinical features of
HIV-infected participants of the study are reported in
Table 1. The two cohorts studied were not homogeneous
in terms of CD4+ T-cell counts (175/mm3 vs. 393/mm3,
active TB vs. controls without active TB, p = 0.001).
Response to selected RD1 peptides is associated with 
active TB
Among those with active TB, one sample was unreadable
due to artifacts and one sample was deemed "unrespon-
sive to M. tuberculosis antigens" (CD4+ T-cell count: 154/
mm3) because it tested negative to both selected RD1 pep-
tides and intact proteins (used as positive control). There-
fore these 2 samples were excluded from further analyses.
Among the 28 subjects analyzed, 18 with active TB and 10
without active TB, the median responses to selected ESAT-
Table 1: Demographic and clinical characteristics of HIV-infected subjects enrolled in the study
Active TB
N. 20 (%)
No Active TB
N. 10 (%)
Female (%) 13 (65) 8 (80)
Age, median (years) 32 31
BCG vaccinated 20 (100) 10 (100)
HIV-RNA, median (cpmL) 21675 11870
CD4+ T-cells
Median (cells/μL) 175 393
101–200 11 (55) 0
201–300 8 (40) 2 (20)
≥ 301 1 (5) 8 (80)
BCG: Bacillus Calmette and Guerin; HIV: Human immunodeficiency virus; Cpm: copies per ml; TB: tuberculosis.BMC Infectious Diseases 2008, 8:11 http://www.biomedcentral.com/1471-2334/8/11
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6 peptides (40 spot-forming cells [interquartile range
{IQR}, 0–414 spot-forming cells] vs. 17 spot-forming
cells [IQR, 0–298 spot-forming cells] p = 0.09) and
selected CFP-10 peptides (83 spot-forming cells [IQR,
18–580 spot-forming cells] vs. 14 spot-forming cells [IQR,
0–288 spot-forming cells]; p = 0.1) were not significantly
higher in the group with active TB, compared with the
control group. Conversely the sum of ESAT-6 and CFP-10
peptide responses (167 spot-forming cells [IQR, 38–816
spot-forming cells] vs. 30 spot-forming cells [IQR, 10–550
spot-forming cells]; p = 0.02) was significantly higher in
the group with active TB, compared with the group with-
out active disease (Figure 1A).
As internal control, the response to RD1 proteins was
evaluated. The median responses to ESAT-6 protein (63
spot-forming cells [interquartile range {IQR}, 4–384
spot-forming cells] vs. 31 spot-forming cells [IQR, 6–306
spot-forming cells] p = 0.5), CFP-10 protein (63 spot-
forming cells [IQR, 0–612 spot-forming cells] vs. 14 spot-
forming cells [IQR, 0–196 spot-forming cells]; p = 0.1)
and the sum of ESAT-6 and CFP-10 protein responses
(143 spot-forming cells [interquartile range {IQR},
14–996 spot-forming cells] vs. 40 spot-forming cells [IQR,
6–474 spot-forming cells] p = 0.2), were not significantly
different in the two groups, with or without active TB (Fig-
ure 1B).
Next we evaluated whether there was a correlation
between the response to the selected RD1 peptides and
the virological status of the patients. An inverse correla-
tion between the response to RD1 peptides and HIV load
was found although not statistically significant (p = 0.06).
Thus, based on these results, the response to the com-
bined ESAT-6 and CFP-10 peptides was associated with
active TB better than the response to the single pool of
peptides and proteins (either considered singularly or as
the response to the sum of ESAT-6 and CFP10 proteins).
Consequently, hereafter, we report only the analysis of the
sum of ESAT-6 and CFP-10 data, either peptides or pro-
teins.
Evaluation of the response to RD1 epitopes over time and 
correlation with clinical, microbiological and radiological 
data
To evaluate changes in T-cell responsiveness to RD1 pep-
tides during TB treatment 12 cases were followed over
time, at the time of TB diagnosis and after 6 months of
successful therapy leading to culture sputum negativiza-
tion. Nine of them were studied also after 3 months of
therapy.
The median of the sum of ESAT-6 and CFP-10 peptide
response at diagnosis (236 [IQR, 38–816 spot-forming
cells], after 3 months of therapy (74 [IQR, 4–470 spot-
forming cells]) and after 6 month at therapy completion
(100 [IQR, 14–602 spot-forming cells] were analyzed
(Figure 2A). A significant decrease of the response was
found between baseline and 6 months after therapy (p =
0.007). If the responses were evaluated by a qualitative
scoring, a conversion to negative at the completion of
treatment was found in 3/12 patients.
When the response to RD1 proteins was evaluated, no sta-
tistically significant change was observed over time, with
median values of 167 [IQR, 14–996 spot-forming cells],
103 [IQR, 0–646 spot-forming cells] and 100 [IQR, 2–698
spot-forming cells] respectively at diagnosis and after 3
and 6 months of therapy (Figure 2B) (p = 0.1 for the com-
parison of the results at the time of diagnosis vs. comple-
tion of therapy). If the responses were evaluated by a
qualitative scoring, a conversion to negative at the com-
pletion of treatment was found in 3/12 patients.
Next we evaluated the relationship between the RD1
responses and microbiological and radiological features.
No correlation was found between the quantitative
response to selected RD1 peptides, M. tuberculosis load in
sputum (smear and culture) and the radiological lesions
(evaluated by the extension of lung lesions [28]) (data not
shown).
Based on the results described, we conclude that a success-
ful therapy for TB causes a significant decrease of the sum
of ESAT-6 and CFP-10 selected peptide response.
Stratification of responses by CD4+ T-cell counts
The response to RD1 tests are mainly CD4-mediated [16],
and will therefore be influenced by the absolute CD4+ T-
cell count, especially in those with HIV infection. We
therefore stratified the ELISPOT results by CD4+ T-cell
counts.
Among subjects with active TB, the CD4+ T-cell count sig-
nificantly correlated with the sum of ESAT-6 and CFP-10
peptide response (r2:0.47; p = 0.001) (Figure 3A), and
with the sum of ESAT-6 and CFP-10 protein responses
(r2:0.28; p = 0.02) (Figure 3B). However no firm conclu-
sions can be drawn on the correlation between the CD4+
T-cell counts and RD1 responses, as the exclusion of one
outlier result (one subject with very high CD4+ T-cell
counts and spot-forming cells for peptides and proteins,
544/mm3, 816 and 996 spot-forming cells per million
PBMC respectively) renders the correlation coefficients
not statistically significant for both responses to selected
RD1 peptides (r2:0.04; p = 0.4) and proteins (r2:0.01; p =
0.6).BMC Infectious Diseases 2008, 8:11 http://www.biomedcentral.com/1471-2334/8/11
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A-B IFN-gamma ELISPOT response to antigens of Mycobacterium tuberculosis in HIV+ subjects Figure 1
A-B IFN-gamma ELISPOT response to antigens of Mycobacterium tuberculosis in HIV+ subjects. A) Response to 
selected RD1 peptides and B) to RD1 proteins, are shown as spot-forming cells (SFC) per 106 PBMCs. Shaded symbols indi-
cate individuals with tuberculosis (TB patients) and unshaded symbols indicate individuals without tuberculosis (No active TB). 
Horizontal lines indicate median values. The TB patient group had a significantly higher response to the sum of ESAT-6 and 
CFP-10 peptides compared with the group without active TB (p = 0.02).
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A-B. Significant decrease of IFN-gamma response to selected RD1 peptides over time in HIV+ patients with active TB disease Figure 2
A-B. Significant decrease of IFN-gamma response to selected RD1 peptides over time in HIV+ patients with 
active TB disease. A) Response to the sum of ESAT-6 and CFP-10 peptides and B) to the sum of ESAT-6 and CFP-10 pro-
teins in terms of IFN-gamma spot-forming cells (SFCs) per million PBMC for each individual at the time of diagnosis and 6 
months after therapy are reported. For 9/12 individuals data are reported also after 3 months of therapy. The p value denotes 
the difference between the responders in each group.
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A-B. Significant correlation between the response to RD1 antigens and CD4+ T-cell count in HIV-infected individuals with  active-TB Figure 3
A-B. Significant correlation between the response to RD1 antigens and CD4+ T-cell count in HIV-infected indi-
viduals with active-TB. A) Response to the sum of ESAT-6 and CFP-10 peptides and B) to the sum of ESAT-6 and CFP-10 
proteins in terms of IFN-gamma spot-forming cells (SFCs) per million PBMC for each individual are reported and correlated 
with the CD4+ T-cell count per mm3. The p value denotes the statistical significance of the correlation between CD4+ T-cell 
count and the response to the assay.
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Considering the approach suggested by Rangaka et al.
[24], we then calculated the frequency of the RD1
responses in relationship to the CD4+ T-cell counts. In
particular the ratio defined by the ELISPOT counts (per
million PBMC) for each antigen divided by the CD4+ T-
cell counts was determined. The median value of these
ratios for both assays, RD1 peptides and proteins, was sig-
nificantly higher in the active TB group than that in the
control group (Table 2). Then we explored the possibility
of using this approach to better identify the patients with
active TB. We used the ratio data to perform a receiver-
operator characteristic (ROC) analysis, using the groups
with and without active disease as comparator groups
(Figure 4A–B). Significant results for area under the curve
(AUC) analysis were obtained for the sum of ESAT-6 and
CFP-10 peptides (AUC, 0.88; P = 0.0009; 95% CI,
0.72–1.0). Interestingly, a ratio higher than 0.21 predicted
active TB with 100% sensitivity (95% CI, 81%–100%)
and 80% specificity (95% CI, 44%–97%) (Figure 5A).
In addition when considering the sum of ESAT-6 and CFP-
10 proteins, (AUC, 0.77; P = 0.01; 95% CI, 0.57–0.97), a
ratio higher than 0.22 predicted active TB with 89% sensi-
tivity (95% CI, 81%–100%) and 70% specificity (95% CI,
34%–93%) (Figure 5B). No statistically significant differ-
ence was found between the AUC of the RD1 peptides and
protein assay (p = 0.4), although the accuracy of the RD1
peptide test was higher.
Thus, based on these results, in HIV+ patients the use of a
ratio of combined ESAT-6 and CFP-10 ELISPOT count
divided by the CD4+ T-cell count may be a more accurate
tool for the diagnosis of active TB compared to the use of
the number of spot-forming cells. Moreover, by this
approach the accuracy of the assay based on RD1 peptides
is higher compared to that based on RD1 proteins.
Discussion
This pilot study demonstrates that also in developing
countries the response to selected RD1 peptides is associ-
ated with active pulmonary TB in HIV-infected individu-
als. Moreover the response to peptides significantly
decreases after efficacious therapy for TB disease. Further-
more a ratio of combined ESAT-6 and CFP-10 peptide
ELISPOT count divided by the CD4+ T-cell count greater
than 0.21 had 100% sensitivity and 80% specificity for
active pulmonary TB. To our knowledge this is the first
study performed in a TB endemic region of the world in
which a concomitant evaluation of the response to a test
based on RD1 antigens, CD4+ T-cell counts, HIV load and
performance over time of sputum culture for M. tuberculo-
sis was carried out in HIV+ patients with active TB.
In this study the RD1 response correlates with the CD4+ T-
cell number, although weakly. The patients studied had
CD4+ T-cell counts above 100/μl. Among them the HIV-
related immunosuppression did not affect the qualitative
response to selected RD1 peptides. In fact among those
with active TB only one patient resulted incapable of
responding to M. tuberculosis-specific antigens. Moreover
the absolute number of spot-forming cells in response to
the RD1 peptide was significantly lower in those without
active TB compared to those with active disease in spite of
a significant higher number of CD4+ T-cells. This indicates
that the test is not influenced by CD4+ T-cell counts and
has good chances of identifying active TB. Nevertheless,
an impairment of this assay may be expected in presence
of severe immunosuppression (i.e. CD4+ T-cell counts
under 100/μl), as previously reported [19,31].
From the literature it is known that commercial RD1
assays, based on intact CFP-10 and ESAT-6 proteins and
on pools of overlapping peptides spanning the whole
length of these proteins [23-26], detect both latent TB
infection (LTBI) and active TB disease [20-26]. Conversely
the response to the selected RD1 peptides is associated
with active M. tuberculosis replication [15-17]. These dif-
ferences may be related to the amount and the composi-
tion of epitopes covered by the different peptides or by the
whole intact protein used in the diverse tests. As previ-
ously reported the response to the selected RD1 peptides
is mediated by CD4+ T effector cells, shown to undergo
clonal expansion during M. tuberculosis replication, fol-
lowed by a contraction phase after efficacious therapy cul-
minating in the generation of CD4+ memory T-cells [16].
The present study shows for the first time that RD1 T-cell
responses decrease in HIV/TB patients after successful
therapy for TB, confirming the results obtained in patients
without HIV disease [32-35]. The trend of decrease is in
line with previous reports using the ELISPOT technology
[32-35] indicating that these responses better correlate
with bacterial burden than whole blood tests [36]. Here
conversion to negative response to selected RD1 peptides
was found only in 30% of the patients analyzed, differ-
ently from our previous study in which this was found in
100% of the patients after successful therapy [15]. This
may relate to different settings under which the test was
done, as reported by others [36]. In particular a potential
re-exposure to M. tuberculosis, a likely scenario in endemic
countries, after the completion of treatment or to environ-
mental mycobacteria, commonly encountered in the trop-
ics, which share the esat-6 and cfp-10 genes may account
for the diverse finding.
A decrease of RD1-specific CD4+ T-cell effector responses
has been reported also in animal models of M. tuberculosis
infection in which a decrease in responses in mononu-
clear cells from both the lymph nodes and lungs after the
acute phase of infection was shown [37]. This model has
been confirmed by studies performed in patients with dis-BMC Infectious Diseases 2008, 8:11 http://www.biomedcentral.com/1471-2334/8/11
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A-B. A higher ratio of the response to RD1 antigens in relation to CD4+ T-cell count is associated with active TB in HIV+ sub- jects Figure 4
A-B. A higher ratio of the response to RD1 antigens in relation to CD4+ T-cell count is associated with active 
TB in HIV+ subjects. ELISPOT counts per million PBMC for each antigen were divided by the corresponding total CD4+ T-
cell count per mm3 and were plotted against CD4+ T-cell counts. Shaded symbols indicate patients with TB and unshaded sym-
bols indicate individuals without TB. A) For the response to selected RD1 peptides, a ratio in the TB group (shaded symbols) 
higher than 0.21 predicted active TB with 100% sensitivity and 80% specificity). B) For the response to RD1 proteins, a ratio in 
the TB group (shaded symbols) higher than 0.22 predicted active TB with 89% sensitivity and 70% specificity.
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A-B. ROC curves of the tests based on the ratio of the response to RD1 antigens in relation to CD4+ T-cell counts Figure 5
A-B. ROC curves of the tests based on the ratio of the response to RD1 antigens in relation to CD4+ T-cell 
counts. A ratio defined by the result obtained when the ELISPOT counts per million PBMC for each antigen were divided by 
the corresponding total CD4+ T-cell count per mm3 was used to perform a receiver-operator characteristic analysis, using the 
group with active TB and the subjects without active disease as comparator groups. A) ROC curve for the response to RD1 
selected peptides. A ratio higher than 0.21 predicted active TB with 100% sensitivity and 80% specificity. B) ROC curve for the 
response to RD1 intact proteins. A ratio higher than 0.22 predicted active TB with 89% sensitivity and 70% specificity.
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eases different from TB such as HIV-infected patients
undergoing structured treatment interruption [38], in
whom HIV-specific T-cell responses have been reported to
be higher at the peak of viremia and then to decrease
when therapy is reintroduced [39]. Similarly, in patients
who had been acutely infected with Hepatitis C Virus and
who cleared the infection, high frequencies of effector T-
cells are found soon after infection, whereas higher fre-
quencies of memory T-cells appear later on [40].
According to the literature [24], our analysis of these
responses suggests that the ELISPOT test could be incor-
porated into practice in the context of HIV infection. A
positive result to the sum of ESAT-6 and CFP-10 peptide
response per 106 PBMC divided by the CD4+ T-cell count
greater than 0.21 would strongly suggest active disease
that should be investigated and treated. In the present
study, the ratio found for the assay based on intact RD1
proteins is different compared to that reported by Ran-
gaka et al. [24], probably reflecting the fact that the assay
based on RD1 proteins is not standardized (different con-
centration of proteins and ELISPOT reagents). However
since the response to RD1 tests are mainly CD4-mediated
[16], we think it is important, especially in HIV+ patients,
to analyze the RD1 responses in a context of CD4+ T-cell
number, at least for those tests that are still not standard-
ized [24,41].
Specificity of the test based on selected RD1 peptides was
80%. False positive results may be attributed at least in
part to the high prevalence of LTBI and/or elevated prob-
ability of high risk exposure to M. tuberculosis that can be
expected in high TB endemic countries. It would be
important to evaluate if this assay is capable of predicting
onset of TB disease in those without active TB that resulted
positive. Currently all the controls of this study are fol-
lowed over time.
This is a pilot study which presents limitations that will
require additional work to be overcome. Above all, the
study was performed on a relatively small number of indi-
viduals and certainly the research would benefit from a
larger study taking into account type of antiretroviral ther-
apy, if performed, and concomitant diseases. Nevertheless
this pilot study comprised several tests with several corre-
lations performed (two RD1 tests with multiple antigens;
correlation with CD4+ T-cell count; comparison with viro-
logical and microbiological data) indicating that the
response to selected RD1 peptide assay is associated with
active pulmonary TB in HIV-infected individuals from an
African country.
Conclusion
In conclusion the assay based on selected RD1 peptides
may be useful in the design of larger studies in the tropical
setting, to better evaluate the performance of such test in
countries at high endemia of TB.
List of abbreviations
￿ AUC: area under the curve
￿ BCG: Bacillus Calmette Guerin
￿ Cpm: copies per ml
￿ CI: confidence interval
￿ CFP: culture filtrate protein
￿ ELISPOT: enzyme linked immune spot
￿ ESAT: early secreted antigenic target
￿ FACS: fluorescence activated cell sorter
￿ HIV: Human Immunodeficiency Virus infection
￿ IFN: interferon
￿ IGRA: IFN-gamma release assays
￿ IQR: interquartile range
￿ LTBI: Latent tuberculosis infection
￿ PBMC: peripheral blood mononuclear cells
Table 2: IFN-gamma ELISPOT ratio between the sum of ESAT-6 and CFP-10 peptides SFC per million PBMC and the CD4+ T-cell 
counts/mm3 in patients with or without active TB.
Median of IFN-gamma ELISPOT ratio (interquartile range)a
Active TB
N = 18
No Active TB
N = 10
p
Sum of ESAT-6 and CFP-10 peptides 0.92 (0.24–2.23) 0.08 (0–1.46) 0.001b
Sum of ESAT-6 and CFP-10 proteins 0.80 (0.07–4) 0.13 (0.02–1.23) 0.02b
a IFN-gamma ELISPOT ratio (spot-forming cells per 106 PBMCs) for each antigen was divided by the total CD4+ T-cell count per mm3, as previously 
shown (24). b Statistically significant.
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￿ RD: region of difference
￿ RD1: CFP-10 and ESAT-6
￿ ROC: receiver-operator characteristic
￿ SFC: spot-forming cells
￿ TST: tuberculin skin test
￿ TB: Tuberculosis
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